Kai Xu, Johan F Langenhuijsen, Charlotte L Viëtor, Richard A Feelders, Tessa M van Ginhoven, Yasir S Elhassan, Fabio Bioletto, Mirko Parasiliti-Caprino, Wouter T Zandee, Schelto Kruijff, Samuel Backman, Tobias Åkerström, Christina Pamporaki, Nicole Bechmann, Charlotte Lussey-Lepoutre, Letizia Canu, Rebecca V Steenaard, Natacha Driessens, Marieke Velema, Koen M A Dreijerink, Anton F Engelsman, Henri J L M Timmers, Joanne M de Laat
{"title":"PRAP 研究--遗传性嗜铬细胞瘤肾上腺部分切除术与根治术的比较。","authors":"Kai Xu, Johan F Langenhuijsen, Charlotte L Viëtor, Richard A Feelders, Tessa M van Ginhoven, Yasir S Elhassan, Fabio Bioletto, Mirko Parasiliti-Caprino, Wouter T Zandee, Schelto Kruijff, Samuel Backman, Tobias Åkerström, Christina Pamporaki, Nicole Bechmann, Charlotte Lussey-Lepoutre, Letizia Canu, Rebecca V Steenaard, Natacha Driessens, Marieke Velema, Koen M A Dreijerink, Anton F Engelsman, Henri J L M Timmers, Joanne M de Laat","doi":"10.1093/ejendo/lvae108","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Hereditary pheochromocytoma (hPCC) commonly develops bilaterally, causing adrenal insufficiency when standard treatment, radical adrenalectomy (RA), is performed. Partial adrenalectomy (PA) aims to preserve adrenal function, but with higher recurrence rates. This study compares outcomes of PA versus RA in hPCC.</p><p><strong>Methods: </strong>Patients with hPCC due to pathogenic variants in RET, VHL, NF1, MAX, and TMEM127 from 12 European centers (1974-2023) were studied retrospectively. Stratified analysis based on surgery type and initial presentation was conducted. The main outcomes included recurrence, adrenal insufficiency, metastasis, and mortality.</p><p><strong>Results: </strong>The study included 256 patients (223 RA, 33 PA). Ipsilateral recurrence rates were 9/223 (4%) after RA versus 5/33 (15%) after PA (P = 0.02). Metastasis and mortality did not differ between groups. Overall, 103 patients (40%) underwent bilateral adrenalectomy either synchronously or metachronously (75 RA, 28 PA). Of these, 46% developed adrenal insufficiency after PA.In total, 191 patients presented with initial unilateral disease, of whom 50 (26%) developed metachronous contralateral disease, most commonly in RET, VHL, and MAX. In patients with metachronous bilateral disease, adrenal insufficiency developed in 3/4 (75%) when PA was performed as the first operation followed by RA, compared to 1/7 (14%) when PA was performed as the second operation after prior RA (P = 0.09).</p><p><strong>Conclusion: </strong>In patients with hPCC undergoing PA, local recurrence rates are higher than after RA, but metastasis and disease-specific mortality are similar. Therefore, PA seems a safe method to preserve adrenal function in patients with hPCC, in cases of both synchronous and metachronous bilateral disease, when performed as a second operation.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"345-353"},"PeriodicalIF":5.3000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PRAP study-partial versus radical adrenalectomy in hereditary pheochromocytomas.\",\"authors\":\"Kai Xu, Johan F Langenhuijsen, Charlotte L Viëtor, Richard A Feelders, Tessa M van Ginhoven, Yasir S Elhassan, Fabio Bioletto, Mirko Parasiliti-Caprino, Wouter T Zandee, Schelto Kruijff, Samuel Backman, Tobias Åkerström, Christina Pamporaki, Nicole Bechmann, Charlotte Lussey-Lepoutre, Letizia Canu, Rebecca V Steenaard, Natacha Driessens, Marieke Velema, Koen M A Dreijerink, Anton F Engelsman, Henri J L M Timmers, Joanne M de Laat\",\"doi\":\"10.1093/ejendo/lvae108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Hereditary pheochromocytoma (hPCC) commonly develops bilaterally, causing adrenal insufficiency when standard treatment, radical adrenalectomy (RA), is performed. Partial adrenalectomy (PA) aims to preserve adrenal function, but with higher recurrence rates. This study compares outcomes of PA versus RA in hPCC.</p><p><strong>Methods: </strong>Patients with hPCC due to pathogenic variants in RET, VHL, NF1, MAX, and TMEM127 from 12 European centers (1974-2023) were studied retrospectively. Stratified analysis based on surgery type and initial presentation was conducted. The main outcomes included recurrence, adrenal insufficiency, metastasis, and mortality.</p><p><strong>Results: </strong>The study included 256 patients (223 RA, 33 PA). Ipsilateral recurrence rates were 9/223 (4%) after RA versus 5/33 (15%) after PA (P = 0.02). Metastasis and mortality did not differ between groups. Overall, 103 patients (40%) underwent bilateral adrenalectomy either synchronously or metachronously (75 RA, 28 PA). Of these, 46% developed adrenal insufficiency after PA.In total, 191 patients presented with initial unilateral disease, of whom 50 (26%) developed metachronous contralateral disease, most commonly in RET, VHL, and MAX. In patients with metachronous bilateral disease, adrenal insufficiency developed in 3/4 (75%) when PA was performed as the first operation followed by RA, compared to 1/7 (14%) when PA was performed as the second operation after prior RA (P = 0.09).</p><p><strong>Conclusion: </strong>In patients with hPCC undergoing PA, local recurrence rates are higher than after RA, but metastasis and disease-specific mortality are similar. Therefore, PA seems a safe method to preserve adrenal function in patients with hPCC, in cases of both synchronous and metachronous bilateral disease, when performed as a second operation.</p>\",\"PeriodicalId\":11884,\"journal\":{\"name\":\"European Journal of Endocrinology\",\"volume\":\" \",\"pages\":\"345-353\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2024-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ejendo/lvae108\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejendo/lvae108","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
目的:遗传性嗜铬细胞瘤(hPCC)通常为双侧发病,在进行标准治疗,即根治性肾上腺切除术(RA)时,会导致肾上腺功能不全。肾上腺部分切除术(PA)旨在保留肾上腺功能,但复发率较高。本研究比较了 PA 与 RA 对 hPCC 的治疗效果:回顾性研究了来自 12 个欧洲中心(1974-2023 年)的因 RET、VHL、NF1、MAX 和 TMEM127 的致病变异而导致的 hPCC 患者。根据手术类型和初始表现进行了分层分析。主要结果包括复发、肾上腺功能不全、转移和死亡率:研究共纳入 256 例患者(223 例 RA,33 例 PA)。RA术后同侧复发率为9/223(4%),PA术后同侧复发率为5/33(15%)(P=0.02)。两组的转移率和死亡率没有差异。总体而言,103 名患者(40%)同步或同步接受了双侧肾上腺切除术(75 例 RA,28 例 PA)。其中,46%的患者在PA术后发展为肾上腺功能不全。总共有191名患者最初为单侧疾病,其中50人(26%)发展为并发对侧疾病,最常见的是RET、VHL和MAX。在患有双侧并发症的患者中,3/4(75%)的患者在首次进行PA手术后又进行了RA手术,而1/7(14%)的患者在首次进行PA手术后又进行了RA手术(P=0.09):结论:在接受 PA 的 hPCC 患者中,局部复发率高于 RA 后,但转移率和疾病特异性死亡率相似。因此,无论是同步还是近同步双侧疾病,PA似乎都是保留hPCC患者肾上腺功能的一种安全方法。
PRAP study-partial versus radical adrenalectomy in hereditary pheochromocytomas.
Objective: Hereditary pheochromocytoma (hPCC) commonly develops bilaterally, causing adrenal insufficiency when standard treatment, radical adrenalectomy (RA), is performed. Partial adrenalectomy (PA) aims to preserve adrenal function, but with higher recurrence rates. This study compares outcomes of PA versus RA in hPCC.
Methods: Patients with hPCC due to pathogenic variants in RET, VHL, NF1, MAX, and TMEM127 from 12 European centers (1974-2023) were studied retrospectively. Stratified analysis based on surgery type and initial presentation was conducted. The main outcomes included recurrence, adrenal insufficiency, metastasis, and mortality.
Results: The study included 256 patients (223 RA, 33 PA). Ipsilateral recurrence rates were 9/223 (4%) after RA versus 5/33 (15%) after PA (P = 0.02). Metastasis and mortality did not differ between groups. Overall, 103 patients (40%) underwent bilateral adrenalectomy either synchronously or metachronously (75 RA, 28 PA). Of these, 46% developed adrenal insufficiency after PA.In total, 191 patients presented with initial unilateral disease, of whom 50 (26%) developed metachronous contralateral disease, most commonly in RET, VHL, and MAX. In patients with metachronous bilateral disease, adrenal insufficiency developed in 3/4 (75%) when PA was performed as the first operation followed by RA, compared to 1/7 (14%) when PA was performed as the second operation after prior RA (P = 0.09).
Conclusion: In patients with hPCC undergoing PA, local recurrence rates are higher than after RA, but metastasis and disease-specific mortality are similar. Therefore, PA seems a safe method to preserve adrenal function in patients with hPCC, in cases of both synchronous and metachronous bilateral disease, when performed as a second operation.
期刊介绍:
European Journal of Endocrinology is the official journal of the European Society of Endocrinology. Its predecessor journal is Acta Endocrinologica.
The journal publishes high-quality original clinical and translational research papers and reviews in paediatric and adult endocrinology, as well as clinical practice guidelines, position statements and debates. Case reports will only be considered if they represent exceptional insights or advances in clinical endocrinology.
Topics covered include, but are not limited to, Adrenal and Steroid, Bone and Mineral Metabolism, Hormones and Cancer, Pituitary and Hypothalamus, Thyroid and Reproduction. In the field of Diabetes, Obesity and Metabolism we welcome manuscripts addressing endocrine mechanisms of disease and its complications, management of obesity/diabetes in the context of other endocrine conditions, or aspects of complex disease management. Reports may encompass natural history studies, mechanistic studies, or clinical trials.
Equal consideration is given to all manuscripts in English from any country.